BLOG/🇮🇳India··daily

India IPO Pipeline SEBI Regulatory Filings — March 10, 2026

India IPO Pipeline

3 high priority3 total filings analysed

Executive Summary

The India IPO Pipeline stream highlights momentum in listings and post-IPO execution alongside strategic infrastructure M&A, with two new positive developments in Adani Enterprises' acquisition completion and Artemis Electricals' NSE listing approval, while Mahamaya Lifesciences reports neutral progress on IPO proceeds utilization. Period-over-period trends show mixed signals: DPJ TOT (Adani acquiree) revenue grew 20.5% overall from FY23 ₹122 Cr to FY25 ₹147 Cr but slowed sharply to 2.8% YoY in FY25 from 17.2% in FY24, indicating flattening growth; Mahamaya utilized only 44% (₹27.47 Cr of ₹61.96 Cr) of IPO proceeds by Feb 28, 2026, due to execution delays. Critical developments include Artemis' Main Board listing effective March 12, 2026 (25.1 Cr shares), signaling robust IPO pipeline completion, and Adani's full control of DPJ TOT at ₹1,342 Cr EV, expanding road infra footprint. Portfolio-level patterns reveal accelerating IPO listings (2/3 filings) amid neutral post-IPO deployment risks, with infrastructure M&A providing diversification. Market implications point to short-term listing pops for new entrants and long-term infra growth for Adani, tempered by utilization delays in lifesciences.

Tracking the trend? Catch up on the prior India IPO Pipeline SEBI Regulatory Filings digest from March 09, 2026.

Investment Signals(11)

  • Adani Enterprises↓(BULLISH)
    ▲

    Completed acquisition of remaining 49% in DPJ TOT at ₹1,342 Cr EV (Sep 30, 2025), making it wholly-owned subsidiary via ARTL, expanding road infra portfolio post 51% stake in Feb 2026

  • Adani Enterprises↓(BULLISH)
    ▲

    DPJ TOT turnover up 20.5% overall FY23-FY25 (₹122 Cr to ₹147 Cr), with 17.2% YoY FY24 growth outperforming FY25's 2.8% slowdown, strategic arm's length deal per Sep 2025 SPA

  • Artemis Electricals↓(BULLISH)
    ▲

    NSE listing approval for 25,10,36,900 shares (Re. 1 FV) on Main Board effective March 12, 2026 (symbol AEPL), completing IPO process with BSE intimation

  • Artemis Electricals↓(BULLISH)
    ▲

    High materiality 10/10 IPO listing milestone, no financial disruptions disclosed, positioning for post-listing liquidity and trading debut

  • Mahamaya Lifesciences↓(NEUTRAL-BULLISH)
    ▲

    Board approved rescheduling of ₹34.49 Cr unutilised IPO proceeds to March 31, 2028 without changing original objects from Nov 2025 Prospectus, funds parked compliantly

  • Mahamaya Lifesciences↓(NEUTRAL)
    ▲

    44% utilization of ₹61.96 Cr net IPO proceeds (₹27.47 Cr used by Feb 28, 2026), reflecting phased deployment for Technical Manufacturing Plant amid FY26 timing constraints

  • Adani Enterprises↓(BULLISH)
    ▲

    Positive sentiment (8/10 materiality) on DPJ TOT full acquisition (inc. 100% preference shares), aligning with Adani's infra development objectives since 2021 incorporation

  • Artemis Electricals↓(BULLISH)
    ▲

    Positive sentiment IPO listing (10/10 materiality), CIN L51505MH2009PLC196683, strong pipeline signal for electricals sector post-approval

  • Mahamaya Lifesciences↓(BULLISH)
    ▲

    Ongoing Audit Committee and Monitoring Agency oversight per SEBI LODR Reg 32 ensures governance on ₹34.49 Cr unutilised funds

  • Cross-Portfolio(BULLISH)
    ▲

    2/3 filings positive sentiment with IPO listings accelerating vs Adani M&A diversification, outperforming neutral post-IPO update

  • Adani Enterprises↓(BULLISH)
    ▲

    Sequential acquisitions (51% Feb 2026, 49% Mar 2026) at controlled EV, FY25 turnover flat but historical 17.2% YoY FY24 shows recovery potential

Risk Flags(8)

  • Adani Enterprises/Growth Slowdown↓[MEDIUM RISK]
    ▼

    DPJ TOT turnover growth decelerated to 2.8% YoY FY25 from 17.2% FY24 (₹122 Cr FY23 to ₹147 Cr FY25), signaling flat recent performance in road infra

  • Mahamaya Lifesciences/Execution Delay↓[HIGH RISK]
    ▼

    Only 44% (₹27.47 Cr of ₹61.96 Cr) IPO proceeds utilized by Feb 28, 2026, due to limited FY26 window post-Nov 2025 receipt and sequential plant stages

  • Mahamaya Lifesciences/Fund Idle↓[MEDIUM RISK]
    ▼

    ₹34.49 Cr unutilised proceeds rescheduled to Mar 31, 2028, parked in instruments despite procurement cycles, potential opportunity cost vs peers

  • Adani Enterprises/Valuation↓[MEDIUM RISK]
    ▼

    DPJ TOT EV ₹1,342 Cr as of Sep 30, 2025 on FY25 ₹147 Cr turnover (9.1x EV/Revenue), premium to flat growth trajectory

  • Mahamaya Lifesciences/Neutral Sentiment↓[MEDIUM RISK]
    ▼

    Materiality 7/10 with delays cited (project stages, FY26 constraints), lower conviction vs positive Artemis/Adani filings

  • Cross-Portfolio/Utilization Trends[HIGH RISK]
    ▼

    1/3 post-IPO firms (Mahamaya) at partial 44% deployment 4 months post-receipt, outlier vs completed listings/acquisitions

  • Adani Enterprises/Integration↓[LOW-MEDIUM RISK]
    ▼

    Recent full ownership (Mar 10, 2026) of 2021-incorporated DPJ TOT requires monitoring post arm's length SPA execution

  • Mahamaya Lifesciences/Disclosure↓[MEDIUM RISK]
    ▼

    Continued Reg 32 monitoring needed for unutilised funds, any further delays could trigger SEBI scrutiny

Opportunities(8)

Sector Themes(5)

  • IPO Listing Acceleration
    ◆

    2/3 filings mark completions/approvals (Artemis NSE Mar 12, Mahamaya post-IPO update), signaling robust pipeline vs M&A diversion, implies near-term liquidity boosts [INFRA/IPO THEME]

  • Post-IPO Utilization Delays(LIFESCIENCES THEME)
    ◆

    Mahamaya at 44% deployment 4 months in (₹27.47/61.96 Cr), outlier with rescheduling to 2028 due to FY26 constraints, common in capex-heavy sectors

  • Infra M&A Consolidation(INFRA THEME)
    ◆

    Adani's full DPJ TOT ownership (EV ₹1,342 Cr) post 17.2% YoY FY24 growth slowdown, pattern of sequential stakes for control in roads

  • Revenue Growth Moderation(ROAD INFRA THEME)
    ◆

    Acquired entity DPJ TOT flat 2.8% FY25 YoY vs 17.2% FY24 (overall +20.5% FY23-25), potential sector-wide toll road stabilization

  • Positive Sentiment Dominance(IPO PIPELINE THEME)
    ◆

    2/3 positive (Adani/Artemis 8-10/10 materiality) vs 1 neutral, portfolio tilt toward listings over delayed executions

Watch List(7)

Filing Analyses(3)
Adani Enterprises LimitedCompany Updatepositivemateriality 8/10

10-03-2026

Adani Enterprises Limited's wholly-owned subsidiary, Adani Road Transport Limited (ARTL), completed the acquisition of the remaining 49% equity share capital and 100% optionally convertible redeemable preference shares in D P Jain TOT Toll Roads Private Limited (DPJ TOT) on March 10, 2026, making DPJ TOT a wholly-owned subsidiary of ARTL at an enterprise value of ₹1,342 Cr as of September 30, 2025. This strategic move expands Adani's footprint in road infrastructure, aligning with its development objectives. DPJ TOT's turnover grew from ₹122 Cr in FY23 to ₹147 Cr in FY25 (17.2% YoY in FY24 but only 2.8% YoY in FY25, indicating flat recent performance).

  • ·DPJ TOT incorporated on May 6, 2021
  • ·Transaction executed at arm's length per SPA dated September 12, 2025
  • ·Earlier 51% equity acquisition completed February 10, 2026
  • ·All requisite governmental/regulatory approvals received
  • ·Cash consideration paid, subject to closing adjustments
Artemis Electricals and Projects LimitedIPO Listingpositivemateriality 10/10

10-03-2026

Artemis Electricals and Projects Limited has received NSE approval (letter NSE/LIST/246 dated March 10, 2026) for listing 25,10,36,900 equity shares of Re. 1/- each fully paid up on the NSE Main Board, effective March 12, 2026. The company has intimated BSE pursuant to SEBI LODR Regulations. This marks the completion of the IPO listing process with no financial performance data disclosed.

  • ·Stock Symbol: AEPL (EQ series)
  • ·Face Value: Re. 1/- each fully paid up
  • ·CIN: L51505MH2009PLC196683
  • ·Registered Office: Artemis Complex, Gala no 105 & 108, National Express Highway, Vasai (East), Thane, MH 401208
MAHAMAYA LIFESCIENCES LIMITEDIPO Listingneutralmateriality 7/10

10-03-2026

Mahamaya Lifesciences Limited's Board approved via circular resolution on March 10, 2026, rescheduling the utilization of unutilised IPO proceeds of ₹3,449.03 L (₹34.49 Cr) up to March 31, 2028, with no change in the original objects from the November 14, 2025 Prospectus. Out of the proposed ₹6,196.43 L (₹61.96 Cr) from net IPO proceeds, only ₹2,747.40 L (₹27.47 Cr) has been utilized as of February 28, 2026, representing partial deployment amid execution delays. The rescheduling accounts for factors like limited FY 2025-26 window post-November 2025 receipt, sequential project stages for the new Technical Manufacturing Plant, and procurement cycles, while funds remain parked in compliant instruments.

  • ·IPO proceeds received in November 2025
  • ·Unutilised proceeds parked in permitted interest-bearing instruments
  • ·Continued monitoring and disclosure per Regulation 32 of SEBI LODR, including Audit Committee review and Monitoring Agency reporting
  • ·No variation in project scope, configuration, intended capacity, or overall utilisation

Get daily alerts with 11 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 3 filings

Subscribe nowBrowse all digests

🇮🇳 More from India

View all →

March 26, 2026

India Pre-Market Regulatory Roundup — March 26, 2026

India Pre-Market Regulatory Roundup

March 26, 2026

India Quarterly Results BSE NSE Announcements — March 26, 2026

India Quarterly Results BSE NSE Announcements

March 26, 2026

India Upcoming Corporate Actions BSE NSE — March 26, 2026

India Upcoming Corporate Actions BSE NSE

March 26, 2026

India MCA Insolvency Liquidation Filings — March 26, 2026

India MCA Insolvency Liquidation Filings

← All India digests
India IPO Pipeline SEBI Regulatory Filings — March 10, 2026 | Gunpowder Blog